Filing Details
- Accession Number:
- 0000950170-24-128208
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-18 21:12:24
- Reporting Period:
- 2024-11-14
- Accepted Time:
- 2024-11-18 21:12:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1183765 | Molecular Templates Inc. | MTEM | () | V8 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 924223 | Ag Biotech Bb | Schwertstrasse 6 Schaffhausen V8 CH-8200 | No | No | No | No | |
| 1259870 | V N Target Biotech | Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1 Curacao P8 00000 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-11-14 | 1,279,820 | $0.66 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Prefunded Warrants (right to buy) | Acquisiton | 2024-04-02 | 134,667 | $2.35 | 134,667 | $0.00 |
| Common Stock | Common Warrants (right to buy) | Acquisiton | 2024-04-02 | 769,334 | $0.13 | 769,334 | $2.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 134,667 | 2024-04-02 | No | 4 | P | Direct | |
| 769,334 | 2024-04-02 | 2029-04-02 | No | 4 | P | Direct |
Footnotes
- The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.
Billionaire Hedge Funds
